Subscribe to RSS
DOI: 10.4103/0971-5851.151796
Commentary on 19 th annual scientific meeting of the Society for Neuro-Oncology
Abstract
The Society for Neuro-Oncology (SNO) is the premier organization dedicated to the cause of central nervous system (CNS) tumors. Although it is primarily located in North America, it attracts considerable memberships from all over the world with truly multi-disciplinary representations from not only neuro-oncology, neurosurgery, radiation oncology, medical oncology and basic scientists, but also in recent years from imaging, psychology, epidemiology, public health and industry, etc. SNO annual meetings are very much looked forward to with presentations of the latest cutting edge data as well as several educational sessions for trainees and updates for senior members too. The meeting is unique in the way that almost the entire scientific agenda is based on submitted abstracts with very few invited lectures.
Publication History
Article published online:
12 July 2021
© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol 2014:15:943-53.
- 2 Buckner J, Shaw E, Pugh S, et al. R9802: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade qlioma: Results by histologic type. 19th Annual Meeting of the Society for Neuro-Oncology, Abstract AT-13.
- 3 Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802. J Clin Oncol 2012;30:3065-70.
- 4 Verhaak R, Lavarone A. Integrated genomic analysis of low grade glioma and glioblastoma reveals molecular stratification by IDH status across grades and histologies. 19 th Annual Meeting of the Society for Neuro-Oncology, Abstract GE-37.
- 5 Wen P, Reardon D, Phuphanich S. A randomized double blind placebo-controlled phase 2 trial of dendritic cell (DC) vaccine ICT-107 following standard treatment in newly diagnosed patients with GBM. 19 th Annual Meeting of the Society for Neuro-Oncology, Abstract AT-60.
- 6 Gilbert M, Yuan Y, Wani K, et al. A phase II study of lapatinib and dose-dense temozolomide (TMZ) for adults with recurrent ependymoma: A CERN clinical trial. 19 th Annual Meeting of the Society for Neuro-Oncology; Abstract AT-23.
- 7 Jalali R, Gupta T, Goswami S, et al. Randomized trial of high-precision conformal radiation therapy compared to conventional radiotherapy in preservation of long-term neuro-cognitive outcomes in young patients with progressive or residual benign/low-grade brain tumors. 19 th Annual Meeting of the Society for Neuro-Oncology; Abstract PT-06.
- 8 Stupp R, Wong E, Scott C, et al. Interim analysis of the EF-14 trial: A prospective, multicenter trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM. 19 th Annual Meeting of the Society for Neuro-Oncology, Abstract NT-40.